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PSORIASIS AND OTHER SKIN DISORDERS 
FK 506: A New Therapeutic Agent for Severe Recalcitrant Psoriasis 
K. Abu-Elmagd, D. Van Thiel. B.V. Jegasothy. C.D. Ackerman. S. Todo. J.J. Fung. A.W. Thomson. and 
T.E. Starzi 
BETWEEN 12 and 18 months ago we treated three patients with FK S06 who had severe psoriasis that 
was refractory to conventionai therapy and four patients 
with w,despread incidental psonasis before undergoing 
hean or liver transplantation under FK 506. All had 
dramatic resolution of psonasis. which remaIned in remis-
sion as long as full-dose therapy was provided. Serial skin 
biopsies had a rapid disappearance of the inflammatory 
infiltrate and slower resolution 01 epidermal changes. FK 
506 was well tolerated with onlv minor side effects during 
the 12 to 18 months of observation. 
Circumstantiai evidence for an autoimmune etiology of 
psoriasis is the striking remission of psonatic lesions. 
which can be achieved with cyclosporine. l - l an immuno-
suppressive drug whose use for this pUJ'l)Ose has been 
limited by nephrotoxicity. hypenension. and other dose-
related side effects. We repon here the use of the chemi-
cally unrelated drug. FK 506. which also inhibits T helper 
lymphocyte activation and the synthesis and expression of 
cytokines. 4K~ 
METHODS 
Clinical fealUres are summanzed in Table I. Amelioration ot" 
psonastS In four patients was Incldentaito the pnmary objective of 
hean lone I or livertr:m~plantallon Illiree I. The liver disease In one 
of the tauer patients was caused by methotrexate treatment for 
psoriasiS over a J)Criod of 2 years. The other three pallents had 
severe n:caIcitrant psoriasis that had reSisted the therapies listed 
in Table I. 
Table 2. Psorililia Endpotnta In Thrw NontnI_ ••• Pltlents 
BaIlIN Week 2 Week, W". Now 
Clinical (PASI Scores, 
Patient 5 67.S 27 2.8 0 0 
Patient 6 43.4 5.7 0 0 0 
Patient 7 68.4 34.2 9.8 0 0 
HlstopatnologlC 
Epidermal acantnoslS -++ 
Munro·s mlcroa/lSC8SSeS --+ 
ActiVe cennal Inflammatlon ++++ 
The patients were scored for their psonasis seventy using the 
PSOriasiS Area and Severity Index IPASIl.J The seventy of the 
p$Oriasis was determined lTable 2) by measuring the amount of 
erythema. infiltration. and desquamation usmg a scale of 0-4 10 = 
none. I = slight. 2 = moderate. 3 = severe. 4 '" very severe,. In 
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Table 1. Clinical FeaturM 
No. 
qr~ Rec:ipents 
1 
2-
3 
4 
PSOI'iIIsIa Only 
5 
6 
7 
~ 
36IF 
40IM 
33IF 
28IF 
49IF 
301M 
P~ 
heart 
liver 
liver 
liver 
12 
22 
25 
5 
6 
6 
9 
TClPiC* steroids: UVB + tar 
UVB + tar: metnotrexate 
PUVA: toPlC8lllefOlds mtral8SlOl\8l1l8fOldS: 
m8lholntxate 
T opicaIllerolds: systemIC steroids 
PUVA. UVB:!opaI steroids etreanate 
UVB + tar. topCaI steroids goICIl.M.: metnotrexa18 
UVB + Iar. topCaIll8nIIdS mfJlhOtl .... 
AIlItInIMe ... fJtNA -~ MIl lJIIrII.- A 1:J2O...<IOO Mil: UVB - rf~ B 1280-320 MIl. 
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FK 506 IN TREATING SEVERE PSORIASIS 
. 
Tlible 3. AdvwM Ruction Surveillance to End of Januuy 1911-
1 2 3 4 5 8 7 
Date FK 506 Star1IId 2114.110 6I30.1IO 7/13190 8IMIO 5124Il10 7/18/110 8/27/110 
FK doses at start 0.27 0.30 0.35 0.25 0.28 0.29 0.2 
(mgtkgld) 3 months 0.33 0.20 0.40 0.18 0.10 0.30 0.32 
now 0.21 0.13 0.29 0.18 0.30 0.40 0.32 
FK plasma 1 week 1.4 2.5 4.3 3.4 1.1 2.0 0.8 
(ngImL) 3 montns 1.5 1.0 0.9 1.2 0.4 0.4 0.9 
now 1.1 0.8 0.5 1.4 1.3 0.7 1.2 
Steroid dose at start 20 20 20 20 0 0 0 
(mgIO) 3 months 10 0 10 0 0 0 0 
now 0 0 15 0 0 0 0 
Crannma at start 62 53 53 53 88 80 71 
(,..mauL) 3 IT1OI"IItIs 141 159 ISO 106 106 133 ISO 
now 176 159 159 97 159 159 124 
BUN at start 2.5 3.6 4.3 2.5 2.1 3.2 3.6 
(mmoliLl 3 months 15.7 7.1 13.2 9.6 2.5 7.5 10.4 
now 9.3 11.8 12.8 10.4 10.4 7.1 6.8 
F8S at stan 4.7 4.7 5.7 5.1 5.9 5.1 4.4 
(mmoVLI 3 months ~K9 5.3 6.7 5.4 5.7 ~KP 5.5 
now 5.7 .to 5.0 5.5 5.5 5.5 5.2 
Uric aad at start 636 389 214 280 517 321 357 
(p. moIILI 3 IT1OI"IItIs 565 434 428 464 399 297 410 
now 494 571 476 458 478 303 428 
Mg at start 0.88 0.58 0.66 0.82 0.58 0.82 0.58 
(mmollL) 3 months 0.49 0.49 0.66 0.74 0.58 0.49 0 .• 
now 0.58 0.82 0.70 0.45 0.45 0 .• 
K at start 4.1 3.2 3.5 3.9 ~KP 4.& 4.5 
(mmotlLI 3 montns 4.1 4.1 3.3 5.2 3.8 4.& 4.4 
now 4.6 4.& 4.3' 5.2 4.8 5.0' 4.1 
ChoIes1 at start 4.3 1.7 6.3 3.3 4.5 4.7 3.5 
(mmotlLI 3 monthS 5.3 3.9 5.6 2.9 6.6 3.6 3.8 
now 4.7 4.7 5.4 6.1 3.7 3.8 
8P drugs at start 0 0 0 2 0 0 
nUmDer 3 months 0 0 0 0 
now 0 0 0 
·Par--. ___ unct\IngIICI in AU9I* 1991. 
tFludiOCOiliaUile ___ I. rm,.,.*DUIIlCUdIIF1urinelI. 
the three pauents whose primary diagnosis was psonasis. biopSies terol. uric acid. blood glucose. malllesium. and other electrolytes 
were taken before instituting treatment. 2 weeks later. and when were monitored. A detailed repon of these parameters in a larger 
they were clinically free of lesions. group of psonasis pauents IS reponed elsewhere in this sympo-
Oral FK 506 was stancd at O.IS mg/kg twice daily in the sium.6 
nontransplant pauents and adjusted down or up according to the Development of high blood pressure was quanutated (if present! 
FK 506 plasma levels (measured at 12 hour trough with an by the number of antihypenensive drugs required to maintain a 
enzyme-linked immunoassay, or when there was clinical evidence normotensIve state. H ypcrtcalemia was treated with the min-
of incomplete disease control or toxicity. No other drugs were eraloconicoid f\udroconlsone acetate. Hypomagnesemia was 
used. The transplant recIpients were staned on 0.075 or 0.10 seen but did not require correction. 
intravenous FK S06Id and convened to oral dosing when they 
could eat. Transplant patients aiso had prednisone anitiaily. which RESULTS 
was tapered to the levels shown In Table) by I February 1991. Effect on PsonaslS 
These levels have not changed substantially in the ensuing half 
There was a marked reduction in erythema and scale in all year. 
Complete medical examinations including neurologic assess- seven patients by I week and complete clinical remission 
ment were performed repcated1v. oe~ funcuon. serum cholcs- by 3 weeks (Table 2). The remission has been sustained 
1 
!\ 
3324 
with follow-ups of 12 to 18 months. The three patients 
wnose primary diagnosIs was psoriasis (Table 2) were not 
given steroids or other medications. Improvement of ar-
thritis from which they also sutfered occurred simulta-
neously. 
Serial skin biopsies taken from the active plaques of 
psonasis demonstrated a rapid clearance of the inflamma-
tory infiltrate In the dermis and the neutrophils in the 
stratum corneum. The etfect of FK 506 on the skin 
infiltrate is described elsewhere in this symposium. 7 The 
hyperkeratosis and epidermal acanthosis took longer to 
resolve /Table 2>. In these three patients. efforts to reduce 
FK 506 dosage resulted in beginning reappearance of the 
skin lesions. which promptly disappeared after returning to 
the prior dose. 
The four patients who had organ transplants received 
systemic prednisone postoperauvelv. but their remiSSion 
persisted after lowenng (one easel or stopping the sterOIds 
{three cases) (Table 3), Several montns postoperative Iv 
when there was no eVidence 01 gralt dvsfunctlon. the liver 
recipient whose end-stage nepatlc disease was caused by 
methotrexate therapy (Patient 2) developed small psonat-
ric plaques near the exit site of his T-tube. These disap-
peared with a minor increase In FK 506 dose. 
Toxicity and MetaboliC Changes 
FK 506 doses. plasma levels. and surveillance parameters 
were similar in both nontransplant and transplant patients. 
Temporary trembling. parathesias. and insomnia not re-
quiring dose changes were noted in three patients. In-
creases of serum creatinine or BUN signaled the need for 
downward adjustments. and because of careful attention 
to dose control. there were no alarming patterns of toxicity 
Jt the check POints (Table 3). While stable. the ultimate 
level of these measures was higher In aU patients than at 
the outset. Hirsutism and gingival hvperplasia sometimes 
associated with cyclosponne were not observed with FK 
506. 
ABU-ELMAGC. VAN THIEL JEGASOTHY ET AL 
DISCUSSION 
Complete remission of psoriasis induced by FK 506 was 
evident more qUickly than has been observed with other 
immunosuppressive regimens. In the nontransplant pa. 
tients. the FK 506 doses and plasma levels needed to 
maintain remission were in the same range as required to 
prevent allograft rejection. Efforts to give less FK 506 to 
these patients resulted in reactivation of the psoriasis. In 
one liver recipient a dose reduction caused a minor recur-
rence of psoriasis rather than graft rejecllon. 
Whether the reward of complete control of psoriasis will 
be wonh the risk of long-term therapy with this powerful 
drug wlil be judged with funher observations. In our 
psoriasis series herein reported. follow-ups have been 12 
to 18 months. However. what was seen so far is encour-
aging. The only potentially serious side etfect was nephro-
toxicity with rises an creatinine and BUN. which reo 
\ponded so qUickly to dose reduction that they had 
reached a stable although slightly elevated state at the 
,urveiliance check points. No patient has had an infection. 
Patients with Widespread lesions toften wnh psonauc 
:tnhritis) that rum the quality of life have been eager to take 
the risk. Patients with less severe disease should be 
discouraged from candidacy and treated with less drastic 
means. 
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